Search

Your search keyword '"Luca Richeldi, MD"' showing total 2 results
Start Over Author "Luca Richeldi, MD"
2 results on '"Luca Richeldi, MD"'

1. Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort

Author

Marco Caminati, MD, Alessandro Marcon, PhD, Rachele Vaia, MD, Gianenrico Senna, MD, Matteo Maule, MD, Pierpaolo Marchetti, MD, Jessica Miotti, MD, Giuseppe Argentino, MD, Francesco Blasi, MD, PhD, Giorgio W. Canonica, MD, Enrico M. Heffler, MD, PhD, Pierluigi Paggiaro, MD, Andrea Vianello, MD, PhD, Gabriella Guarnieri, MD, Luisa Brussino, MD PhD, S.S.D.D.U, Cecilia Calabrese, MD PhD, Gianna Camiciottoli, MD, Giovanna E. Carpagnano, MD PhD, Stefano Centanni, MD PhD, Angelo G. Corsico, MD PhD, Maria T. Costantino, MD, Claudia Crimi, MD PhD, Alice D'adda, MD, Simona D'alo, MD, Maria D'amato, MD PhD, Stefano Del Giacco, MD, Fabiano Di Marco, MD PhD, Nicola C. Facciolongo, MD, Manuela Latorre, MD PhD, Eustachio Nettis, MD, Eleonora Nucera, MD, Giovanni Passalacqua, MD, Girolamo Pelaia, MD, Laura Pini, MD PhD, Luisa Ricciardi, MD, Luca Richeldi, MD, Erminia Ridolo, MD PhD, Pierachille Santus, MD PhD, Nicola Scichilone, MD, Giulia Scioscia, MD PhD, Giuseppe Spadaro, MD, Antonio Spanevello, MD PhD, and Paolo Tarsia, MD PhD

Subjects
Severe asthma, Aging, Comorbidities, Lung function, Asthma control, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Aging implies changes in terms of lung function, immune system, and respiratory and extra-respiratory comorbidities. Few studies have specifically addressed the relevance of age on severe asthma burden and control. We aimed to evaluate whether age acts as an independent determinant of asthma severity, in terms of clinical, functional, and inflammatory profile, and to explore potential cofactors that contribute to a more difficult disease control in different age groups. Methods: Patients from Severe Asthma Network Italy (SANI) registry were retrospectively divided in subgroups according to their age. Cutoffs for age were established according to quartiles in order to obtain a comparable number of patients for each group, and then rounded for the sake of simplicity. Results: Overall, 1805 severe asthma patients were analyzed. Lung function represented the most important age-related variable. On the opposite the level of asthma control was not differently distributed among age ranges. In young people the presence of atopy-related comorbidities (allergic rhinitis, atopic dermatitis) predominated, whilst systemic-metabolic and degenerative comorbidities such as diabetes, cardiovascular diseases, anxious-depressive syndrome, and osteoporosis prevailed in elderly. Bronchiectasis and sleep disturbances were significantly associated with age. Conclusions: Despite that it cannot be considered a treatable trait, our study suggests that age should be evaluated within a personalized approach to severe asthma patients, in order to provide a better clinical profiling and a more tailored treatment strategy.

Published
2024
Full Text
View/download PDF

2. ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments

Author

Carlo Lombardi, MD, Riccardo Asero, MD, Diego Bagnasco, MD, Francesco Blasi, MD, Matteo Bonini, MD, Mario Bussi, MD, Rikki F. Canevari, MD, Giorgio Walter Canonica, MD, Paolo Castelnuovo, MD, Lorenzo Cecchi, MD, Lorenzo Cosmi, MD, Matteo Gelardi, MD, Enrico Heffler, MD, Luciana Indinnimeo, MD, Massimo Landi, MD, Amelia Licari, MD, Francesco Liotta, MD, Alberto Macchi, MD, Luca Malvezzi, MD, Gianluigi Marseglia, MD, Claudio Micheletto, MD, Antonino Musarra, MD, Diego Peroni, MD, Giorgio Piacentini, MD, Venerino Poletti, MD, Luca Richeldi, MD, Angela Santoni, MD, Michele Schiappoli, MD, Gianenrico Senna, MD, Adriano Vaghi, MD, Alberto Villani, MD, and Giovanni Passalacqua, MD

Subjects
Nasal polyps, CRSwNP, Biological antibodies, ARIA, Personalized medicine, Immunologic diseases. Allergy, RC581-607
Abstract

In the recent years, it was recognized that type-2 inflammation links many forms of nasal polyposis with severe asthma. Thus, some biological drugs developed for severe asthma appeared to exert an effect on nasal polyposis. So far, there are several trials supporting this concept; therefore, some monoclonal antibodies for severe asthma were assessed also in polyposis, with promising results. Since different specialists are involved in the management of nasal polyposis (eg, pulmonologists, ENT, allergists), it was felt that an educational and informative document was needed to better identify the indications of biologicals in nasal polyposis. We collected the main Italian Scientific Societies, and prepared (under the Allergic Rhinitis and its Impact on Asthma, ARIA) a document endorsed by all Societies, to provide a provisional statement for the future use of monoclonal antibodies as a medical treatment for polyposis. It is the first nationwide endorsed document on this aspect. The current pathogenic knowledge and the experimental evidence are herein reviewed, and some suggestions for a correct prescription and follow-up are provided.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results